RIPRETINIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H21BrFN5O2
Molecular Weight	510.358
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C3=C(Br)C=C(F)C(NC(=O)NC4=CC=CC=C4)=C3

InChI

InChIKey=CEFJVGZHQAGLHS-UHFFFAOYSA-N

InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)

HIDE SMILES / InChI

Molecular Formula	C24H21BrFN5O2
Molecular Weight	510.358
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/31085175 |https://www.deciphera.com/pipeline/ripretinib-dcc-2618/

Ripretinib (DCC-2618) is an investigational, orally available switch control kinase inhibitor being developed for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors driven by tyrosine-protein kinase KIT (KIT) or platelet-derived growth factor alpha (PDGFRα) kinase. Ripretinib acts by forcing the activation loop (or activation "switch") of kinases into an inactive conformation and is a type II kinase inhibitor demonstrated to broadly inhibit activation loop mutations in KIT and PDGFRA, previously thought only achievable with type I inhibitor. Ripretinib is developed by the company Deciphera and is being investigated in phase 3 clinical trials for the treatment of GIST, ASM and other tumors.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Stem cell growth factor receptor 57 Target ID: CHEMBL1936 Sources: DOI: 10.1158/1538-7445.AM2015-2690	Inhibitor 8504	4.0 nM [IC50]
Platelet-derived growth factor receptor alpha 33 Target ID: CHEMBL2007 Sources: DOI: 10.1158/1538-7445.AM2015-2690 \| DOI: 10.1093/annonc/mdx387 \| DOI: 10.1093/neuonc/nox168.002 \| https://www.ncbi.nlm.nih.gov/pubmed/29439183	Inhibitor 8504
Hepatocyte growth factor receptor 56 Target ID: CHEMBL3717 Sources: https://patents.google.com/patent/WO2010051373A1	Inhibitor 8504
Vascular endothelial growth factor receptor 2 112 Target ID: CHEMBL279 Sources: https://patents.google.com/patent/WO2010051373A1	Inhibitor 8504

C_max

Value	Dose	Analyte	Population
1820 ng/mL EXPERIMENT https://doi.org/10.1016/j.ccell.2019.04.006	50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	RIPRETINIB plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
7880 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31085175/	150 mg 2 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:	RIPRETINIB plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
761 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213973s003lbl.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	RIPRETINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
5678 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213973s003lbl.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		RIPRETINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
14.8 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213973s003lbl.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		RIPRETINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213973s003lbl.pdf	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		RIPRETINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.	2019-05-13	31085175
The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.	2018-05	29439183

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:39:20 GMT 2025` Edited by `admin` on `Mon Mar 31 23:39:20 GMT 2025`
Record UNII	9XW757O13D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

QINLOCK

Preferred Name

English

RIPRETINIB

Official Name

English

RIPRETINIB [USAN]

Common Name

English

N-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-N'-PHENYLUREA

Systematic Name

English

UREA, N-(4-BROMO-5-(1-ETHYL-1,2-DIHYDRO-7-(METHYLAMINO)-2-OXO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-N'-PHENYL-

Systematic Name

English

ripretinib [INN]

Common Name

English

Ripretinib [WHO-DD]

Common Name

English

RIPRETINIB [ORANGE BOOK]

Common Name

English

DCC-2618

Code

English

RIPRETINIB [MI]

Common Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/17/1936